Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Pharvaris ( (PHVS) ).
On June 10, 2025, Pharvaris announced its annual general meeting of shareholders scheduled for June 27, 2025. The company is currently advancing its pivotal Phase 3 studies for the prevention and on-demand treatment of HAE attacks, which could significantly impact its market positioning and stakeholder interests.
The most recent analyst rating on (PHVS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock’s overall score is affected by these financial and valuation challenges, despite its technical strength.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists. The company aims to address unmet needs in bradykinin-mediated diseases, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), by providing injectable-like efficacy and placebo-like tolerability with the convenience of oral therapies.
Average Trading Volume: 69,559
Technical Sentiment Signal: Sell
Current Market Cap: $914.4M
Find detailed analytics on PHVS stock on TipRanks’ Stock Analysis page.